Beta-O2 is Proposing a Life-Changing Benefit to Diabetes PatientsBeta-O2 Technologies Ltd. is a biomedical company developing a proprietary implantable bio-artificial pancreas, the ßO2™. This implantable device is designed as a treatment for insulin dependent patients.
The ßO2™ is a small device that is implanted subcutaneously in a quick minimally invasive procedure. The device contains islets of Langerhans (containing insulin-producing cells), which are continuously oxygenated and nourished through Beta-O2's proprietary technology.
The islets of Langerhans in the ßO2™ sense glucose levels in the body and secrete the corresponding levels of insulin necessary to maintaining normal glucose levels.
This novel technology enables diabetic insulin dependent patients to live with balanced glucose levels and without frequent glucose monitoring and insulin injections.
No more frequent glucose monitoring and insulin injections.